ArticleInflammopharmacology2026
Phosphatidylserine liposomes containing metformin mitigate experimental atopic dermatitis: evidence for Akt/mTOR pathway involvement.
Article in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundAtopic dermatitis (AD) is driven by dysregulated cytokine signaling, oxidative stress, and eicosanoid-mediated inflammation, with current therapies offering incomplete control and safety concerns during long-term use. Metformin has recognized antioxidant and immunomodulatory actions, but its limited ability to traverse the skin barrier constrains topical application. Phosphatidylserine formulations may overcome this limitation by facilitating delivery and regulating inflammatory signaling cascades.
objectiveTo assess the therapeutic efficacy of phosphatidylserine-based metformin formulations (PS-Met) in an oxazolone-induced murine model.
methodsAD was induced in sixty-four female mice through topical oxazolone sensitization and challenge. Animals received 14 days of topical treatment with PS-Met at 0.5%, 1%, or 2%, phosphatidylserine alone, betamethasone, or saline. Clinical scores, pruritus-related behaviors, histopathology, cytokine and oxidative stress markers, cyclooxygenase-1/2 expression, and protein kinase B (Akt)/mammalian target of rapamycin (mTOR) signaling pathway were evaluated.
resultsPS-Met produced dose-dependent therapeutic effects, with the 1% and 2% formulations showing pronounced responses. These treatments reduced macroscopic dermatitis scores, epidermal thickening, collagen deposition, and pruritus-related behaviors. Serum immunoglobulin E and malondialdehyde were decreased, while superoxide dismutase and interleukin-10 levels were restored. PS-Met also lowered interleukin-1β, interleukin-12, and interleukin-31, reduced nitroblue tetrazolium activity, selectively suppressed cyclooxygenase-2, and downregulated Akt/mTOR signaling, with the 1% and 2% formulations achieving effects comparable to or exceeding those of betamethasone.
conclusionTopical PS-Met provides multi-targeted improvement in AD by attenuating inflammation, oxidative stress, and key signaling pathways, particularly at 1% and 2% concentrations. While promising, these preclinical findings require validation in chronic models and clinical studies to establish translational relevance.
Indexed as
Identifiers
41642551What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.